Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Mallinckrodt plc, widely recognised simply as Mallinckrodt, is a global specialty pharmaceutical company operating within the pharmaceutical preparation manufacturing industry. Headquartered in Ireland, its origins trace back to 1867, establishing a long legacy in developing essential medicines.
The company is dedicated to developing, manufacturing, and distributing innovative therapies for patients facing severe and critical conditions. Its core focus includes treatments for autoimmune and rare diseases, as well as complex central nervous system disorders, addressing significant unmet medical needs.
Mallinckrodt maintains a strong market presence through its commitment to advancing medical science with a patient-centric approach. The organisation continually invests in research and development to improve health outcomes and deliver vital pharmaceutical solutions worldwide.
+2 vs industry average
Mallinckrodt plc’s score of 44 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Mallinckrodt plc, a Pharmaceutical Preparation Manufacturing company headquartered in Ireland, reported global Scope 1 emissions of approximately 80,934,000 kg CO2e and Scope 2 emissions (location-based) of around 68,201,000 kg CO2e for 2024. Their Scope 3 emissions for the same year totalled approximately 238,157,000 kg CO2e, with significant contributions from purchased goods and services (about 178,886,000 kg CO2e), fuel and energy related activities (around 24,697,000 kg CO2e), capital goods (approximately 12,136,000 kg CO2e), and upstream transportation and distribution (about 22,438,000 kg CO2e).
Looking back, in 2023, Mallinckrodt plc's global Scope 1 emissions were approximately 81,956,000 kg CO2e, and Scope 2 emissions (location-based) were around 73,947,000 kg CO2e. For 2022, global Scope 1 emissions stood at approximately 80,126,000 kg CO2e, with Scope 2 emissions (location-based) at about 82,349,000 kg CO2e. Scope 3 emissions data for 2022 and 2023 is not available.
Mallinckrodt plc has a near-term net-zero commitment to reduce its Scope 1 and Scope 2 emissions to "near zero" by the middle of this decade (2025), with targets established in 2023.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more